Online inquiry

IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14322MR)

This product GTTS-WQ14322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFL7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016215.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51162
UniProt ID Q9UHF1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14322MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3965MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ2808MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ5289MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ13038MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ12911MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ1841MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ10005MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ13481MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW